The Journal of Clinical Endocrinology & Metabolism: January 31, 2013
Context: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny.
Objective: The objective of the study was to characterize the risk of adverse events associated with glucose-lowering therapies in people with T2DM.
Design and Setting: This was a retrospective cohort study using data from the UK General Practice Research Database, 2000–2010.
Patients: Patients comprised 84 622 primary care patients with T2DM treated with one of five glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin monotherapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combination therapy. There were 105 123 exposure periods. Read more